The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1S-1-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.

The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1S-1-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.

The invention relates to a use of a compound for manufacturing a medicament for treating an allergic disease, wherein the compound is selected from the group consisting of ovatodiolide, 1-acetoxychavicol acetate, zerumbone and combination thereof. Also provided is a method and a composition for treating an allergic disease.

The invention relates to a use of a compound for manufacturing a medicament for treating an allergic disease, wherein the compound is selected from the group consisting of ovatodiolide, 1-acetoxychavicol acetate, zerumbone and combination thereof. Also provided is a method and a composition for treating an allergic disease.

The invention relates to a use of a compound for manufacturing a medicament for treating an allergic disease, wherein the compound is selected from the group consisting of ovatodiolide, 1-acetoxychavicol acetate, zerumbone and combination thereof. Also provided is a method and a composition for treating an allergic disease.

The instant invention refers to nanosystems comprising nanocomposites for adsorption or support of natural extracts; a process for the preparation thereof; formulations containing thereof, as well as a nanomaterial that adsorbs one or more essential oils in its surface. Specially, one object of the invention is the encapsulation of natural extracts, i.e., essential oils and/or natural pure bioactive compounds and optionally terpenoid, sesquiterpenoid, diterpenoid, sesterterpenoid, triterpenoid, carotenoid, and ricinoid compounds; complementary acids, and polysaccharides; vitamins, and other organic compounds, in mesoporous materials for application in different industries such as food, agricultural, veterinary, aquacultural, pharmaceutical, cosmetic, cleaning, sanitizing, and disinfection industries, as well as in medicine.

The instant invention refers to nanosystems comprising nanocomposites for adsorption or support of natural extracts; a process for the preparation thereof; formulations containing thereof, as well as a nanomaterial that adsorbs one or more essential oils in its surface. Specially, one object of the invention is the encapsulation of natural extracts, i.e., essential oils and/or natural pure bioactive compounds and optionally terpenoid, sesquiterpenoid, diterpenoid, sesterterpenoid, triterpenoid, carotenoid, and ricinoid compounds; complementary acids, and polysaccharides; vitamins, and other organic compounds, in mesoporous materials for application in different industries such as food, agricultural, veterinary, aquacultural, pharmaceutical, cosmetic, cleaning, sanitizing, and disinfection industries, as well as in medicine.

A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91.sup.phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.

A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91.sup.phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.

A pharmaceutical composition for treating eczema is disclosed. The pharmaceutical composition includes, by weight, 2 to 6 parts of Dried Rhizoma Zingiberis Officinalis, 2 to 6 parts of Paeonia Lactiflora, 1 to 4 parts of Fructus Amomi, 0.5 to 3 parts of Semen Alpiniae Katsumadai, 0.5 to 3 parts of Inula helenium, 0.5 to 3 parts of Radix Et Rhizoma Rhei and 0.5 to 3 parts of Rhizoma Dioscoreae. The components of the pharmaceutical composition synergistically cooperate to clear and disinhibit the liver and gallbladder and clear away damp heat from the body. The pharmaceutical composition can be used to treat skin eczema symptoms caused by metabolic disorders of the liver and gallbladder functions. A method for preparing the pharmaceutical composition is also disclosed.